LONG MINI-FUTURE - NOVO-NORDISK B | Delayed Deutsche Boerse AG 12:52:31 03/06/2024 BST | ||
| 20.38 EUR | -0.59% |
|
| 1 month | +3.48% | ||
| 3 months | +14.91% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 03/06/24 | 20.38 | -0.59% |
| 31/05/24 | 20.5 | +0.34% |
| 30/05/24 | 20.43 | +0.59% |
| 29/05/24 | 20.31 | -0.25% |
| 28/05/24 | 20.36 | +0.05% |
Delayed Quote Deutsche Boerse AG
Last update June 03, 2024 at 12:52 pm
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VF8M4B |
| ISIN | DE000VF8M4B7 |
| Date issued | 02/08/2019 |
| Strike | 156.6 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.41 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 21.08 € |
|---|---|
| Lowest since issue | 0.23 € |
| Spread | 0.01 € |
| Spread % | 0.05% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Certificates
- Certificat
